A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

A groundbreaking study by researchers from Mass General Brigham and Washington University School of Medicine in St. Louis has ...

In a paper recently published in the leading journal "The Lancet Digital Health", a scientific team led by Stanisa Raspopovic from MedUni Vienna looks at the progress and challenges in the research ...

A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...

President and Acting President of UT Health San Antonio, Taylor Eighmy, has appointed Francisco G. Cigarroa, M.D., as the ...